Genomic Vision SA is a leading company that focuses on the development of innovative genomic solutions. With a strong commitment to the advancement of genetic research, the company values excellence, collaboration, and integrity. Genomic Vision SA follows a corporate philosophy aimed at improving human health through cutting-edge technology and accurate genetic analyses. By leveraging their expertise in molecular combing and genomic profiling, Genomic Vision SA is dedicated to providing reliable and efficient diagnostic solutions for various genetic diseases. With its emphasis on progress and scientific excellence, Genomic Vision SA strives to contribute to the betterment of healthcare and the understanding of human genetics.

Genomic Vision SA is primarily present in various countries and regions across the world. With its headquarters in France, the company has a strong presence in Europe, including countries like Germany, the United Kingdom, Spain, Italy, and Switzerland. Additionally, Genomic Vision SA has established significant operations and partnerships in North America, particularly in the United States and Canada. The company also has a growing presence in Asia, with a focus on countries like China, Japan, and South Korea. Genomic Vision SA's global reach showcases its commitment to expanding its innovative genomic analysis solutions worldwide.

Genomic Vision SA has achieved several significant milestones in its history. One notable achievement is the development of the proprietary Molecular Combing technology, which enables the direct visualization and analysis of single DNA molecules. This groundbreaking innovation has positioned Genomic Vision SA as a leader in genetic testing and diagnostics. Additionally, the company has successfully collaborated with renowned research institutions and industry partners to validate its technology and expand its applications in various fields, including cancer research, rare genetic diseases, and agrigenomics. With its continuous efforts in advancing genomic medicine, Genomic Vision SA is making notable contributions to the field of molecular diagnostics.

Genomic Vision SA is a leading biotechnology company specializing in molecular diagnostics and analysis of genetic diseases. Founded in 2004 and headquartered in France, Genomic Vision aims to revolutionize genetic testing through its innovative molecular combing technology. This technique enables the direct visualization and study of the genome structure, allowing for the identification of genetic abnormalities and the development of personalized medicine. Genomic Vision has also established strategic partnerships with renowned institutions and industry leaders to further advance its proprietary technology. With its dedication to driving precision medicine, Genomic Vision SA continues to make significant contributions to the field of genomics and enhance the lives of patients worldwide.

The main competitors of Genomic Vision SA in the market include companies such as Illumina, Inc., Thermo Fisher Scientific Inc., Pacific Biosciences of California, Inc., and Bionano Genomics, Inc. These companies operate in the field of genomics and offer technologies and solutions related to genetic analysis and molecular diagnostics. They compete with Genomic Vision SA in terms of developing innovative genomic platforms, products, and services to cater to the needs of various industries, including healthcare, pharmaceuticals, research institutions, and more.

Genomic Vision SA is primarily active in the biotechnology and healthcare industries.

The business model of Genomic Vision SA revolves around developing and commercializing innovative molecular diagnostic solutions for genetic diseases and cancer. Their proprietary technology, known as molecular combing, allows for the identification and analysis of genetic abnormalities with high precision and sensitivity. By partnering with pharmaceutical and biotech companies, Genomic Vision SA aims to provide personalized and reliable diagnostics that can guide treatment decisions and enable targeted therapies. This business model positions Genomic Vision SA as a leader in the field of molecular diagnostics, offering valuable insights into the understanding, prevention, and management of genetic disorders and oncology.

Genomic Vision에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

Genomic Vision에 대한 현재 KUV는 계산할 수 없습니다.

Genomic Vision에 대한 AlleAktien 품질 점수는 6/10입니다.

Genomic Vision에 대한 현재 매출은 계산할 수 없습니다.

Genomic Vision의 현재 이익을 계산할 수 없습니다.

Genomic Vision SA is a French biotechnology company specializing in the development and commercialization of molecular genetic solutions for research, diagnosis, and treatment of genetic diseases. The company was founded in 2004 and has its headquarters in Bagneux, France.

Genomic Vision은(는) 연간 번의 배당을 통해 0 EUR의 배당금을 지급합니다.

Genomic Vision의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Genomic Vision의 ISIN은 FR0011799907입니다.

Genomic Vision의 WKN은 A110TM입니다.

Genomic Vision의 티커는 GV.PA입니다.

지난 12개월 동안 Genomic Vision은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Genomic Vision은(는) 0 EUR의 배당금을 지급할 것으로 예상됩니다.

Genomic Vision의 현재 배당 수익률은 입니다.

Genomic Vision은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Genomic Vision은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 EUR의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Genomic Vision은 '건강' 섹터에 속합니다.

Genomic Vision의 마지막 배당금을 0 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Genomic Vision는 0 EUR를 배당금으로 지급했습니다.

Genomic Vision의 배당금은 EUR에 지급됩니다.